We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

This study has been withdrawn prior to enrollment.
(IRB delayed their review for an extensive period of time. Funding for this protocol is no longer available.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01069432
First Posted: February 17, 2010
Last Update Posted: January 26, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Dartmouth-Hitchcock Medical Center
  Purpose
The purpose of this study is to collect a blood sample from patients with Chronic Lymphocytic Leukemia (CLL) and from volunteers without CLL.

Condition Intervention
Chronic Lymphocytic Leukemia Other: No Intervention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

Resource links provided by NLM:


Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • To identify the genes that are differentially expressed at the polysomal RNA and protein levels in human patient CLL cells (compared to normal donor lymphocytes) using high-throughput microarray approaches. [ Time Frame: 2 Years ]

Secondary Outcome Measures:
  • To determine whether the novel candidate genes from Specific Aim 1 have potential roles in CLL. (Note: Specific Aim 2 does not involve human subjects research). [ Time Frame: 2 Years ]

Biospecimen Retention:   Samples With DNA
10cc of peripheral blood.

Enrollment: 0
Study Start Date: May 2010
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with CLL
Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
Other: No Intervention
No Intervention
Normal Volunteers
Normal volunteers who have no history of active or prior hematologic malignancy.
Other: No Intervention
No Intervention

Detailed Description:
The blood sample will be used in the laboratory to perform focused studies on Chronic Lymphocytic Leukemia (CLL).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center
Criteria

Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
  • Normal donors who have no history of active or prior hematologic malignancy.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL, other hematologic malignancy or other disease process within the past 2 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
  • Normal donors who have a history of steroid use, immunosuppression therapy or autoimmune disease are excluded.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01069432


Locations
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center
  More Information

Responsible Party: Christopher Lowrey, MD, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT01069432     History of Changes
Other Study ID Numbers: D1019
First Submitted: February 15, 2010
First Posted: February 17, 2010
Last Update Posted: January 26, 2012
Last Verified: January 2012

Keywords provided by Dartmouth-Hitchcock Medical Center:
Chronic Lymphocytic Leukemia
CLL
Normal Volunteers

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell